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Abstract 8 
Pain is a prevalent condition that can have a serious impact upon the socioeconomic function of a population.  9 
Numerous methods exist to administer analgesic medication (e.g. aspirin) to the body however inherent 10 
drawbacks limit patient acceptability.  The inhaled route offers promise to facilitate the administration of 11 
medication to the body.  Here, we consider the crystallisation behaviour of aspirin, our model therapeutic 12 
agent, when in contact with material of relevance to the lung.  Thus, our approach aims to better understand 13 
the interaction between drug substances and the respiratory tract.  Langmuir monolayers composed of a 14 
mixed surfactant system were supported on an aqueous subphase containing aspirin (7.5mg/ml).  The 15 
surfactant film was compressed to either 5mN/m (i.e. inhalation end point) or 50mN/m (i.e. exhalation end 16 
point), whilst located within a humid environment for 16 hours.  Standard cooling crystallisation procedures 17 
were employed to produce control samples.  Antisolvent crystallisation in the presence or absence of lung-18 
specific additives was conducted.  All samples were analysed via scanning electron microscopy (SEM) and X-ray 19 
diffraction (XRD).  Drug-surfactant interactions were confirmed via condensed Langmuir isotherms.  SEM 20 
analysis revealed plate-like morphology.  The crystallisation route dictated both the crystal habit and particle 21 
size distribution.  Dominant reflections were the (100) and (200) aspects.  The main modes of interaction were 22 
hydrogen bonding, hydrophobic associations and van der Waals forces.  Here, we have demonstrated the 23 
potential of antisolvent crystallisation with lung-specific additives to achieve control over drug crystal 24 
morphology.  The approach taken can be applied in respirable formulation engineering. 25 
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1. Introduction 39 
 40 
Pain is associated with a number of well-documented disease states; including for example rheumatoid 41 
arthritis, malignant disease and conditions of idiopathic origin [1].  Consequently, pain is a prevailing complaint 42 
that presents worldwide and within the United Kingdom it is estimated that thousands of people experience 43 
the issue on a daily basis [2].  The presentation of pain can result in a significant reduction in quality of life and 44 
may affect socioeconomic function [3].  Pain management is routinely achieved through the administration of 45 
analgesic medication via the oral, transdermal or parenteral routes.  Although the more traditional routes of 46 
analgesic drug delivery to the body hold merit (e.g. ease of use and dose flexibility) several drawbacks do exist 47 
(e.g. discomfort at the injection site and variable bioavailability).  Accordingly, interest in alternative, more 48 
patient friendly methods to administer analgesic medication to the body has gained pace; one such example is 49 
that of the inhaled route [4].   50 
The lung serves as an effective portal for drug delivery to the body due to the large surface area for 51 
absorption, the highly vascularised nature of the organ plus the thin, moist air-blood barrier [5].  The delivery 52 
of particulate material to the respiratory tract is an inefficient process, with typically only 20% of the emitted 53 
dose reaching the lung and contacting pulmonary surfactant [6].  This notable inefficiency may be ascribed to a 54 
number of factors, including for example material cohesion / adhesion, particle size distribution along with 55 
particle morphology [7].  Thus, in order to maximise the availability of drug substance for therapeutic benefit, 56 
a formulation should exhibit the best possible combination of physicochemical characteristics (e.g. particle size 57 
(optimal range between 1µm - 5μm), shape, crystal form, solubility, bioavailability and stability).  Of 58 
significance to the work presented herein, it is the morphology of the respirable material (and hence exposed 59 
chemical functionalities) that will principally govern the interaction profile between an active pharmaceutical 60 
ingredient (API) and pulmonary surfactant [8].   61 
 62 
 63 
 64 
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On delivery to the (deep) lung, an aerosolised formulation will initially interact with pulmonary surfactant               65 
[9 & 10].  This material is a complex biological mixture that lines the inner surface of the lung (i.e. the alveolar 66 
space) and reduces the surface tension term to maintain airway patency [11].  During the process of tidal 67 
breathing, variation in pulmonary surfactant physical characteristics occurs [12], which can in turn influence 68 
the processes of drug particle dissolution and subsequent absorption [13].  The principal components of 69 
pulmonary surfactant are saturated dipalmitoylphosphatidylcholine (DPPC), unsaturated phosphatidylcholines, 70 
phosphatidylglycerols (i.e. 1-palmitoyl-2-oleyl-sn-glycero-3-phosphatidylglycerol (POPG)) along with the 71 
surfactant proteins (SP) A, B, C and D [14 & 15].  Absence of this endogenous material in new born infants 72 
results in the precipitation of respiratory distress syndrome (RDS).  This condition may be effectively managed 73 
by the intratracheal administration of commercially available pulmonary surfactant replacement preparations 74 
(i.e. Survanta®).  Often such products are supplemented with palmitic acid (PA) to achieve a representative 75 
lipid – protein profile.  The chemical structures of DPPC, POPG and PA are presented in Figure 1. 76 
 77 
 78 
 79 
 80 
 81 
 82 
Figure 1. The molecular structures of (a) DPPC, (b) POPG and (c) PA. 83 
 84 
 85 
 86 
 87 
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Langmuir monolayers may be applied within the laboratory setting to investigate the structure-function 88 
activity of pulmonary surfactant [16, 17, & 18].  The experimental approach may also be exploited to stimulate 89 
epitaxial nucleation and facilitate controlled crystal growth [19].  Here, the presence of an ordered two-90 
dimensional surface in proximity to a solubilised API can serve to reduce the activation energy necessary for 91 
crystal nucleation when compared to similar homogenous media.  As such, the model may be applied to 92 
investigate the chemical complementarity between APIs / biologically relevant molecules at the alveolar air-93 
liquid interface.  Indeed, the potential of Langmuir monolayers to stimulate crystal formation was successfully 94 
demonstrated by Mu and co-workers during 2005, whereby the group employed DPPC monolayers to induce 95 
and control glycine crystal development [20].  Various operating parameters were noted to influence resultant 96 
crystal habits; including for instance the pH of the subphase and monolayer surface pressure.  Flexibility in 97 
operating conditions can thus afford the formulator with scope to achieve control over crystalline properties 98 
(e.g. exposed surface chemistries). 99 
Although Langmuir monolayers hold potential to inform understanding surrounding API nucleation and crystal 100 
growth within simulated pulmonary environments, several drawbacks (e.g. low crystal yield plus large particle 101 
size distribution) preclude use for industrial scale-up and patient end-use.  Therefore, it is necessary to 102 
investigate alternative routes of crystallisation, such as antisolvent crystallisation with biologically relevant 103 
additives, to achieve controlled crystal growth and support chemical complementarity with appropriate yields.  104 
The strategy involves the addition of a second solvent (i.e. ethanol) to a supersaturated, drug-containing 105 
solution to reduce drug solubility and initiate crystallisation [21].  Typically, this approach is rapid and 106 
generates a large number of micron-sized drug particles that are suitable for delivery to the (deep) lung.  This 107 
particular methodology was applied by Xie and co-workers in 2010, whereby a range of additives were used to 108 
achieve control over drug crystal size and form [22].  Here, the group crystallised salbutamol sulphate in the 109 
presence of compounds such as hydroxypropylmethylcellulose and demonstrated an influence on crystal 110 
development, morphology and size distribution.  The authors linked the findings to the capability of the 111 
additives to interact favourably with specific chemical groupings on drug crystal surfaces and thus inhibit 112 
growth.   113 
 114 
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Aspirin has been selected as the model API for study.  This agent is administered extensively via the oral route 115 
within the clinical setting to manage both acute pain and inflammation [23].  The molecule comprises of a 116 
benzene ring, carboxylic acid and acetylated phenol groupings.  Here, the intention is to obtain an improved 117 
understanding as to how intrinsic chemical moieties within a drug molecule can influence the interaction with 118 
lung-specific material (i.e. DPPC, POPG and PA) and thus govern crystal presentation.   119 
Aspirin exerts its effect by irreversibly inactivating both the cyclo-oxygenase (COX)-1 and (COX)-2 enzyme 120 
systems [24].  To date, the therapeutic compound has been subject to extensive investigation [25, 26, 27 & 121 
28].  As such, aspirin is known to exist as two polymorphs (i.e. form I and form II) [25, 27 & 28].  Typically, form 122 
I dominates, however in 2005 Vishweshwar and co-workers solved the structure for aspirin form II, both being 123 
very similar in terms of internal molecular ordering [25, 26 & 29].  Aspirin form I exists with the monoclinic 124 
space grouping of P21/c [28] having unit cell parameters of a = 11.23(3), b = 6.54(10), c = 11.23(3) Å,  = 125 
95.89, V = 821.218 Å3 [28 & 30].   126 
This study aims to investigate the crystallisation behaviour of aspirin when exposed to simulated pulmonary 127 
surfactant monolayers and biologically relevant components of such.  The work will provide an insight into the 128 
morphologies of resultant aspirin crystals and enable the determination of important functionalities at the 129 
dominant solid interfaces that may underpin the interaction with the alveolar air-liquid interface.  130 
 131 
 132 
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2. Materials and Methods 145 
 146 
2.1 Materials 147 
 148 
The starting material, aspirin with ≥99.0% purity (Lot: 080M0092V), was purchased from Sigma-Aldrich, UK.  149 
The surfactants DPPC (Avanti Polar Lipids, USA. Lot: 160PC-299), POPG (Avanti Polar Lipids, USA. Lot: 160-150 
181PG-113) and PA (Sigma-Aldrich, UK. Lot: 087K1877) were of analytical grade and used as supplied.  151 
Chloroform (CHCl3) (Sigma-Aldrich, UK) employed as the spreading solvent was of analytical grade (≥ 99.9%).  152 
Ethanol (HPLC grade, Sigma-Aldrich, UK) was used as the antisolvent in this work.   Ultrapure water (Elga, UK), 153 
demonstrating a resistivity of 18.MΩcm, was used both during cleaning procedures and as the aqueous 154 
subphase.  155 
2.2 Methods 156 
 157 
 158 
2.2.1 Aspirin Batch Crystallisation 159 
 160 
 161 
A saturated solution of aspirin with a concentration of 7.5mg/ml was produced in 20ml of ultrapure water 162 
heated to 40°C in a jacketed beaker connected to a circulating water bath (ThermoHaake DC10, USA) and 163 
subsequently stirred at 700rpm. The solution was rapidly cooled in an ice bath to 1.5°C for an hour and a half 164 
to facilitate crystallisation.  The crystals were recovered via Buchner filtration and dried in an oven at 60°C 165 
overnight. The resultant crystals were later analysed via scanning electron microscopy (SEM) and X-ray 166 
diffraction (XRD).  167 
        2.2.2      Aspirin Antisolvent Crystallisation 168 
 169 
A saturated solution of aspirin with a concentration of 100mg/ml was produced in 10ml of ethanol. 170 
Subsequently, a total of 30ml of ultrapure water (i.e. the antisolvent) was heated to 20°C in a jacketed beaker 171 
connected to a circulating water bath (ThermoHaake DC10, USA) and placed on a heating stage with a 172 
magnetic stirrer.  The aspirin solution was added drop wise to the ultrapure water with vigorous stirring.  The 173 
drug-containing solution was agitated for a period of 10 minutes.  Resultant crystals were recovered via 174 
Buchner filtration and dried in an oven at 60°C overnight.  The approach was repeated with DPPC (1% and 5%), 175 
POPG (1% and 5%) and PA (1% and 5%) in the aspirin solution.   176 
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The relatively low percentage strengths were chosen during this aspect of the study so as not to dominate the 177 
crystallisation environment (i.e. as apparent in the Langmuir trough) and also align with budgetary constraints. 178 
        2.2.3        Langmuir Monolayers 179 
 180 
Surfactant monolayers were produced using a Langmuir trough (Model 102M, Nima Technology, UK).  181 
Surfactant free tissues (Kimtech Science, Kimberley-Clark Professional, 75512, UK) were soaked in chloroform 182 
and used to clean all the glassware and contacting surfaces.  Test runs that monitor surface pressure during 183 
barrier compression were performed to ensure cleanliness.  Trough cleanliness was confirmed at 0.4mN/m on 184 
complete barrier compression, in the absence of a surfactant monolayer.   185 
A spreading solution composed of DPPC, POPG and PA in the ratio 69:20:11 was produced by dissolving the 186 
surfactant material in chloroform (1 mg/ml).  In total, 10µl of this solution was delivered to the surface of the 187 
pure water subphase by drop-wise addition using a Hamilton microsyringe and left for 10 minutes to facilitate 188 
chloroform evaporation and surfactant spreading.  The trough barriers were programmed to move to the 189 
centre of the trough at a rate of 30cm2/min.  Plots of surface pressure vs area per molecule (π-A) for the 190 
surfactant system at 25°C were collected using a Wilhelmy plate at the centre of the compartment. 191 
 192 
         2.2.4        Aspirin Recrystallisation beneath Langmuir Monolayers 193 
 194 
Recrystallisation was performed using a drug containing aqueous subphase at concentrations of 7.5mg/ml 195 
aspirin at 25±1°C.  The simulated pulmonary surfactant monolayer was compressed to surface pressures of 196 
5mN/m or 50mN/m and left to stand for 16 hours to facilitate crystallisation.  During collection, the inner 197 
section of the Langmuir trough was isolated then the solid material was collected and subsequently filtered via 198 
a Buchner filter. 199 
 200 
 201 
 202 
 203 
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        2.2.5         Sample Characterisation 204 
 205 
         2.2.5.1       X-ray Diffraction (XRD) 206 
 207 
To complete the XRD investigation, the aspirin crystals recovered from each system were mounted onto a 208 
quartz sample holder.  Diffraction patterns were obtained using Cu radiation (λ = 1.54 Å) at a voltage of 30 kV 209 
and a current of 15 mA with an automatic, variable divergence slit (Rigaku Miniflex, Rigaku corporation, Japan).  210 
Samples were scanned from 3° to 50° 2θ.  Subsequently, the data were compared with those presented in the 211 
literature to characterise the solid form [27].  212 
 213 
        2.2.5.2        Scanning Electron Microscopy (SEM) 214 
 215 
All samples were visualised via SEM analysis (Quanta 200 SEM, FEI, Holland).  At the outset, the material was 216 
palladium coated using a K550X sputter coater (EMITECH, UK) and then scanned using an acceleration voltage 217 
of 10 kV at a working distance of approximately 10mm.  218 
3. Results 219 
 220 
3.1       Langmuir Monolayers 221 
 222 
Langmuir pressure-area isotherms acquired for the mixed surfactant system when supported on either a pure 223 
water or an aspirin containing subphase are presented in Figure 2.  Upon inspection, it is evident that the 224 
presence of the API within the supporting subphase did not adversely affect monolayer dynamics.  Deviation 225 
between each trace does confirm aspirin – simulated pulmonary surfactant interaction.  226 
 227 
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 228 
 Figure 2. Langmuir π-A isotherms for the mixed surfactant systems at 25°C. 229 
 230 
Distinct phase changes over the course of compression are denoted by the variation in recorded gradients 231 
within each trace.  The limiting area per molecule for the mixed system in the absence of aspirin was 232 
approximately 55Å2.  However, further to the inclusion of aspirin within the subphase, the limiting area per 233 
molecule was estimated to be 42Å2.  The notable reduction in this term arises due to the interaction between 234 
those aspirin molecules in solution and the surfactant molecules forming the monolayer structure [19].  The 235 
result may be ascribed to the binding of drug molecules to the underside of the mixed surfactant monolayer, 236 
in turn forming a condensed ensemble.   237 
 238 
 239 
 240 
 241 
 242 
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3.2 Scanning Electron Microscopy  243 
 244 
SEM images relating to aspirin crystals generated by various routes are presented in Figure 3.  Crystalline 245 
particles formed by conventional cooling crystallisation (Figure 3a) exhibited equant morphology and were 246 
large in size (i.e. approximately 370µm x 270µm), thus precluding use for drug delivery to the lung.  The 247 
samples produced via mixed surfactant monolayers at surface pressures of 5mN/m (Figure 3b) and 50mN/m 248 
(Figure 3c) displayed plate-like morphology, with bladed crystals being present in the sample generated at 249 
50mN/m. In the case of both samples, the size of the resultant material would also not permit effective 250 
delivery to the (deep) lung; indicative sizes being 90m x 140m and 100m x 390m, respectively.   251 
With respect to the material produced via antisolvent crystallisation, the particle size was significantly smaller.  252 
Antisolvent crystallisation in the absence of additives produced drug crystals of an irregular nature, which may 253 
be attributed to limited control over the crystallisation process (data not shown).  The inclusion of lung-specific 254 
additives had a profound impact upon crystal size distribution and morphology. In terms of antisolvent 255 
crystallisation in the presence of DPPC 5% (Figure 3d), the crystalline material had a relatively smooth texture 256 
with the sample containing particulates demonstrating cohesive properties.  Here, the typical size range was 257 
35m x 45m.  In terms of the material obtained via antisolvent crystallisation in the presence of POPG 5% 258 
(Figure 3e), plate-like morphology was apparent with some deviation in the size distribution; the 259 
representative particle size was estimated at 90µm x 55µm.  Clearly, within this particular sample the particles 260 
were larger when compared to those obtained with DPPC as the lung-specific additive.  Once again, the 261 
particles demonstrated cohesive properties with agglomerates clearly visible.  The inclusion of PA at 5% (Figure 262 
3f) within the antisolvent reaction vessel once more resulted in the generation of small drug-containing 263 
particulates similar to the DPPC sample; here, the typical size was 35µm x 45µm.  Within this sample plate-like 264 
crystals with smooth surfaces were evident.  Overall, the data indicate that antisolvent crystallisation, in 265 
combination with lung-specific additives, resulted in the presentation of drug-containing particulates that 266 
demonstrated plate-like morphology at geometric diameters within the 10’s of micron size range.  The route of 267 
crystallisation governed the crystal habit. 268 
 269 
 270 
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 289 
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 292 
 293 
Figure 3. SEM images of aspirin crystals produced under various study conditions: a) conventional cooling crystallisation, b) 294 
mixed monolayer at 5mN/m, c) mixed monolayer at 50mN/m, d) antisolvent crystallisation with DPPC 5%, e) antisolvent 295 
crystallisation with POPG 5% f) antisolvent crystallisation with PA 5%. Typical morpholgies included equant and plate-like. 296 
The crystallisation environment dictated gross particle morphology. 297 
 298 
a) b) 
c) d) 
e) f) 
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3.3 Crystal Yield 299 
 300 
Crystal yield data from the various systems under investigation are presented in Figure 4.  Upon inspection of 301 
the data it is evident that the conventional cooling approach resulted in the smallest crystal yield.  This result 302 
may be ascribed to the limited solubility of aspirin in ultrapure water under the predefined experimental 303 
conditions and confirms this route of crystal manufacture would be unsuitable at the industrial scale.  The 304 
application of antisolvent crystallisation with lung-specific additives resulted in the generation of a greater 305 
crystal mass, which may be attributed to the increased capacity for drug solubilisation within each system.  As 306 
the concentration of each specific additive was increased, the yield from each antisolvent system also 307 
increased. 308 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
 316 
Figure 4. Crystal yield data from the systems under investigation. The inclusion of lung-specific additives at higher 317 
percentages increased the crystal yield. 318 
 319 
Inhibition of crystal growth was most notable in the case of antisolvent crystallisation in the presence of PA at 320 
the 1% level, with 78.7mg of material generated.  Conversely, antisolvent crystallisation in the presence of PA 321 
at 5% concentration resulted in the largest recoded yield.  Of particular note is the mass obtained from the 322 
antisolvent crystallisation POPG 5% system.  Here, a relatively large amount of drug-containing crystalline 323 
material (i.e. 424.7mg) was recovered.  Interestingly, the XRD diffraction pattern for this particular sample 324 
reflected that obtained from the crystalline material obtained from the mixed surfactant monolayers at 325 
5mN/m and 50mN/m. 326 
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3.4 X-ray Diffraction Analysis 327 
 328 
The crystalline material recovered from each system under investigation was subject to XRD examination; 329 
representative traces are illustrated in Figure 5.  Analysis was conducted on ‘as synthesised’ samples, such that 330 
dominance within the morphology could be determined; this approach has been applied in previous crystal 331 
elucidation studies [31 & 32].  All intensity values were converted to relative values (e.g. percentages) to 332 
highlight subtle changes in aspirin morphology under variable experimental conditions.   333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
Figure 5.  XRD analysis of aspirin crystals recovered from each system under investigation.   The route of crystallisation 345 
holds a significant bearing on the material acquired from each system.  With the Langmuir trough crystallisation 346 
environment in mind, similarity is most evident in the case of the antisolvent system with POPG at the 5% level.  Thus, the 347 
data indicate that the latter route of particle manufacture would be most suitable for material scale up to ensure internal 348 
lung surface complimentarity. 349 
 350 
 351 
 352 
 353 
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The diffraction data highlight that there is a clear difference between the aspirin crystals produced under pre-354 
determined conditions.  The preferred orientation noted reflects the area of the face on which the crystals are 355 
lying and the morphology of the material.  With respect to the conventional cooling sample, the (200) face 356 
demonstrates a reflection of 52%, with the (300) and (400) facets showing reflections of 10% and 15%, 357 
respectively; the XRD pattern matches those previously determined for single aspirin crystals [28]. The XRD 358 
profile of the as synthesised sample by antisolvent crystallisation with PA 5% is comparable to the XRD pattern 359 
for ground sample [32], this reflecting the size and morphology of the crystal.  360 
The XRD patterns for the other systems show a clear difference in preferred orientation, which to a certain 361 
extent reflects the difference in the morphology [31].  As anticipated, the dominant reflection presenting 362 
within the sample produced via the conventional cooling method was the (100) facet.  This particular reflection 363 
is expected to govern the crystal morphology of aspirin form I because the material was grown in water and is 364 
assigned a space grouping of P21/c [27 & 28].  The (100) reflection within the sample was applied to confirm 365 
the remaining faces associated with the material.  Here, additional readings at 2θ values of 15.81°, 23.83° and 366 
31.9° suggest the presence of the (200), (300) and (400) reflections, respectively [27].   367 
The XRD data acquired from the mixed monolayer system at 5mN/m demonstrates dominance in the (100) 368 
reflection.  This result may be ascribed to the conditions under which the crystals were allowed to grow (i.e. an 369 
aqueous environment).  An interesting point to note with this sample is the increase in percentage intensity 370 
associated with the (200) face when compared to the cooling crystallisation sample.  Here, the reflection 371 
demonstrates 85% which represents a 23% increase.  With regard to the crystalline aspirin sample acquired 372 
from the mixed surfactant system at 50mN/m, it is apparent that close similarity exists with that obtained 373 
from the lower surface pressure.  That is to say, the (100) facet dominates the situation with the (200) 374 
reflection being a close second.  In this case, the (200) reflection presents with a 65% intensity, this figure 375 
being 13% greater than the conventional cooling sample.  The data suggest that the mixed surfactant 376 
monolayers, at both low and high surface pressures, influence the reflection of the (200) face and as such this 377 
face, with associated external chemistries, may indeed be important during the interaction with endogenous 378 
pulmonary surfactant.   379 
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The XRD analysis for aspirin crystals recovered from the antisolvent crystallisation system with DPPC 5% as a 380 
lung-specific additive indicate that a number of reflections present (i.e. a random array of peaks are evident).  381 
Here, the (100) facet presents at 30%, the (200) face at 100%, (300) plane at 51% and (400) plane at 11% 382 
relative intensity.  The application of DPPC at 5% within the antisolvent reaction vessel does not permit 383 
effective control over particle morphology to reflect the simulated pulmonary surfactant systems.  On 384 
inspection of the XRD data for the crystalline material produced with POPG 5% as the lung-specific additive, it 385 
is clear that similarity exists between the diffraction data acquired for the simulated pulmonary surfactant 386 
systems at high and low surface pressure.  We suggest, therefore, that this integral component of endogenous 387 
pulmonary surfactant would be suitable to guide the presentation of aspirin crystals complementary to the 388 
internal surface of the (deep) lung.  Conversely, the inclusion of PA at the 5% level within the reaction vessel 389 
did not favour the production of crystalline particles demonstrating similar diffraction patterns to the mixed 390 
monolayer systems.  In this case, the (100) reflection intensity diminished, whilst the (200), (300) and (020) 391 
reflections dominated within the morphology.  Overall, the XRD data confirm that lung-specific additives can 392 
influence the synthesis of aspirin during the process of antisolvent crystallisation.  Thus, in order to rationally 393 
engineer drug-containing particulates to support interaction with internal lung surfaces, the manufacturing 394 
process and additive must be carefully defined. 395 
 396 
3 Discussion 397 
 398 
During this work stable, simulated pulmonary surfactant monolayers were generated using DPPC, POPG and 399 
PA.  We have previously detailed how the protrusion of related chemical functionalities into the supporting 400 
subphase may attract solubilised APIs and correspondingly reduce the activation energy required for 401 
crystallisation [8 & 18].  In order to better understand the crystallisation mechanism(s) associated with aspirin 402 
when in contact with simulated pulmonary surfactant monolayers or components thereof, consideration must 403 
be given to the underlying chemistries that govern the initial interactions between each species.   404 
 405 
 406 
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DPPC is a zwitterionic molecule that contains anionic hydrogen bond acceptors and a cationic ammonium 407 
group.  The latter, which is at the termini and therefore exposed most prominently to the aqueous layer, has 408 
the potential to form strong interactions with aspirin molecules dissolved in solution.  In particular, the 409 
carboxylate group arising from the dissociation of aspirin in water will associate with the ammonium group via 410 
charge-charge interaction.  The polarised CH bonds of the methyl groups in the ammonium group may also 411 
interact through specific binding interactions with the carboxylate or other hydrogen bond acceptors in the 412 
aspirin.  This functionality will therefore interact most favourably with the (100) face which presents the 413 
carboxylate group.  By contrast, the POPG retains the phosphate oxygens but has the hydrogen bonding 414 
features of the glycerol group in place of the charged features of the ammonium group in DPPC.   These groups 415 
are much better placed to interact with the acetyl group of aspirin with which they can form polar and 416 
hydrophobic interactions.  This amphiphilic behaviour is one of the defining characteristics of glycerol that 417 
underpins its utility in stabilising many compounds during their crystallisation.  The proposed mechanism for 418 
interaction between the species considered herein is presented in Figure 6.  The PA molecule will primarily 419 
present carboxylate on the lower surface of the monolayer and is therefore unlikely to interact constructively 420 
with aspirin.   421 
 422 
 423 
 424 
Figure 6. The proposed mechanism of interaction between key aspirin and POPG functionalities within the simulated 425 
pulmonary surfactant system. 426 
 427 
 428 
 429 
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With respect to aspirin crystals formed beneath the simulated pulmonary surfactant monolayers at 5mNm-1 430 
and 50mNm-1, it is clear that the (100) and (200) planes dominate the scenario.  A similar trend was also noted 431 
in the case of those aspirin crystals recovered from the rapid cooling crystallisation vessel, although in this 432 
particular case the (200) plane was less prominent.  The data confirm that both crystal faces, and associated 433 
chemistries, are important during material synthesis.  The principal crystal faces identified via XRD analysis 434 
were visualised using the Mercury v3.0 software package.  Here, the (100) face predominately involves the 435 
carboxylic acid group.  As illustrated in Figure 7 panel a, this group is positioned across this face in a way that 436 
will maximise interactions between the carboxylic acid and solvent water.  The related (200) face, illustrated in 437 
Figure 7 panel b, is dominated by the acetyl group.  Specifically the carbonyl oxygen and the hydrophobic 438 
methyl group are presented.  This pair of groups is likely to form attractive interactions with the glycerol head 439 
groups of the surfactant molecules, as shown in Figure 1.  Glycerol is known to interact amphiphilically in this 440 
way [33]. 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
 450 
 451 
 452 
Figure 7. The chemical structure of aspirin with key functionalities along with their presentation at the dominant (100) and 453 
(200) crystal planes. 454 
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When considering drug particle delivery to the (deep) lung, the physicochemical changes associated with 455 
pulmonary surfactant during tidal breathing are of importance.  This is so because on initial contact with 456 
internal surfaces in the (deep) lung, respirable drug-containing particles are wetted by pulmonary surfactant 457 
and the related hypophase then subsequently displaced towards the alveolar epithelium [11 & 13].  The extent 458 
of particle immersion is dependent on the surface pressure of the surfactant monolayer, with greater 459 
immersion apparent at a lower surface pressure [13].  During inhalation, the surface area of the alveoli 460 
increases, which leads to a related decrease in surfactant surface pressure; the net effect being lack of 461 
uniformity of the constituent molecules and the availability of polar head groups for interaction.  Conversely, 462 
during exhalation the alveolar surface area decreases and a related increase in the surfactant surface pressure 463 
is noted.  This effect results in a more ordered scenario whereby the hydrocarbon chains of the surfactant 464 
molecules are fully extended towards the alveolar lumen and the polar heads groups associate strongly with 465 
the supporting aqueous subphase.  At this point, both the polar head groups and pulmonary hypophase are 466 
theoretically ‘hidden’ from descending drug particles.   467 
With this in mind, during the breath holding stage of the accepted inhaler technique, rationally engineered 468 
drug-containing particulates may descend upon a pulmonary surfactant monolayer that is in the gaseous 469 
phase and interact with the polar head groups effectively.  Here, we suggest that the extent of particle wetting 470 
and related immersion would be greater; hence, the time lag to reach the systemic circulation would be 471 
reduced leading to more effective systemic presence and related disease treatment (i.e. pain management).    472 
With commercially available respirable formulations in mind, there is no guarantee that such preferred 473 
external chemistries between a drug particle and pulmonary surfactant will come into contact, in effect the 474 
association between each species is essentially uncontrolled. 475 
 476 
 477 
 478 
 479 
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In general, drug particle manufacture within the pharmaceutical industry is often conducted via crude, 480 
uncontrolled crystallisation processes that typically utilise organic solvents.  Further to crystallisation, a drug-481 
containing suspension is typically filtered, dried and subjected to comminution procedures.  Such stages  can 482 
be costly, time consuming, inefficient and can have significant effects on powder stability, flow properties, 483 
energetics and may go so far as to destabilise the crystal structure [34].  As such, alternative methods for 484 
respirable particle manufacture have been investigated, for example spray drying [35].  Although this 485 
particular method is a one-step manufacturing process, the high temperatures that are often used prove 486 
restrictive for thermally liable compounds and often lead to amorphous particle generation [36].  As a result of 487 
such inherent drawbacks, attention is now focussed on alternative crystallisation techniques that involve single 488 
step particle production leading to material with narrow size distribution, optimal aerodynamic parameters 489 
and desirable surface properties, a prime example of this is antisolvent crystallisation.  490 
In 2012 Park and Yeo successfully applied antisolvent crystallisation to synthesise carbamazepine-containing 491 
particulates [21].  Here, the authors considered a wide range of experimental parameters during particle 492 
generation such as solution concentration, crystallisation temperature, solution addition rate and the 493 
application of ultrasound.  The data indicated that as the concentration of the carbamazepine solution was 494 
increased the resultant particle size decreased, which also held true when the temperature of the system was 495 
increased.  Importantly, the group noted that smaller drug-containing particles were generated with rapid 496 
introduction of the antisolvent (10ml/min) compared to larger particles with slower introduction (1.4ml/min); 497 
the average particle size range was reported to be 62.1µm – 112.3µm, respectively.  Moreover, the rate of 498 
antisolvent addition did not influence the crystal habit; hence, exposed chemical moieties remained constant.  499 
Thus, the authors demonstrate that antisolvent crystallisation can provide a route to manufacture drug-500 
containing particulates within a narrow particle size range at the 10’s of micron scale. 501 
 502 
 503 
 504 
 505 
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4 Conclusion 507 
 508 
This study has provided opportunity to better understand the crystallisation behaviour of the commonly 509 
prescribed analgesic agent aspirin when in contact with material located at the alveolar air-liquid interface.  510 
Key crystal planes for consideration during the interaction with simulated pulmonary surfactant, and 511 
components thereof, include the (100) and (200) facets.  Here, we have demonstrated that the crystallisation 512 
environment (i.e. heterogeneous nucleating surface vs antisolvent crystallisation) and the presence of 513 
additives are important in guiding the morphology of drug-containing particulate material.  The understanding 514 
gained may be applied in the rational engineering of drug-containing respirable particulates for local or 515 
systemic disease management. 516 
Whilst this exploratory study (i.e. the combination of unrelated crystallisation techniques to better understand 517 
drug chemical complementarity with the lung) was conducted under ambient conditions, potential exists to 518 
execute such work under physiologically relevant parameters via application of the lung biosimulator [37].  519 
This new development within the field of Langmuir monolayer technology also provides the user with scope to 520 
investigate the impact of environmental toxins (e.g. cigarette / e-cigarette / cannabis smoke) on lung function 521 
[38].  Moreover, the approach has application in the dissolution profiling of orally inhaled products (OIPs) 522 
along with the implementation of in vitro – in vivo correlation studies.  523 
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